Top Page
ASKA Pharmaceutical Holdings Co., Ltd.
(4886)
ASKA Pharmaceutical Holdings Co., Ltd. (4886) vs. iShares MSCI Japan ETF (EWJ)
ASKA Pharmaceutical Holdings Co., Ltd. Business Overview & Revenue Model
ASKA Pharmaceutical Holdings Co., Ltd. Financial Statement Overview
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 63.95B | 64.14B | 62.84B | 60.46B | 56.61B | 55.18B |
| Gross Profit | 31.49B | 31.34B | 30.66B | 28.59B | 26.35B | 25.38B |
| EBITDA | 8.72B | 8.49B | 12.57B | 8.24B | 7.68B | 6.97B |
| Net Income | 5.18B | 5.10B | 7.54B | 4.24B | 4.29B | 2.71B |
Balance Sheet | ||||||
| Total Assets | 91.49B | 100.53B | 90.75B | 87.14B | 83.30B | 82.58B |
| Cash, Cash Equivalents and Short-Term Investments | 10.17B | 11.16B | 17.24B | 17.91B | 17.10B | 10.51B |
| Total Debt | 7.42B | 10.90B | 9.48B | 12.62B | 14.05B | 16.39B |
| Total Liabilities | 26.30B | 31.34B | 28.82B | 32.61B | 34.41B | 38.07B |
| Stockholders Equity | 65.19B | 65.31B | 61.93B | 54.53B | 48.89B | 44.51B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -475.00M | 33.00M | 2.60B | 465.00M | 5.44B |
| Operating Cash Flow | 0.00 | 2.48B | 1.49B | 3.35B | 2.84B | 6.54B |
| Investing Cash Flow | 0.00 | -6.12B | 1.71B | -1.13B | 6.74B | -2.87B |
| Financing Cash Flow | 0.00 | -2.96B | -3.94B | -1.82B | -3.00B | -455.00M |
ASKA Pharmaceutical Holdings Co., Ltd. Technical Analysis
ASKA Pharmaceutical Holdings Co., Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ¥81.80B | 8.67 | 3.31% | 9.83% | 86.18% | ||
76 Outperform | ¥35.38B | 11.51 | 7.10% | 2.93% | 12.06% | -51.89% | |
72 Outperform | ¥61.45B | 12.91 | 2.17% | 6.23% | -31.45% | ||
68 Neutral | ¥38.31B | 20.30 | 4.14% | 7.99% | -51.78% | ||
67 Neutral | €106.68B | 18.45 | 4.88% | 2.55% | 2.74% | 36.86% | |
65 Neutral | ¥343.60B | 11.39 | -0.17% | 2.39% | 9.60% | -12.34% | |
57 Neutral | ¥19.09B | 6.46 | 3.60% | 8.71% | -325.91% |
ASKA Pharmaceutical Holdings Co., Ltd. Corporate Events
ASKA Pharmaceutical Holdings Co., Ltd. reported its consolidated financial results for the first quarter of FY2025, showing an 18.2% increase in net sales compared to the previous year. However, the company experienced declines in operating profit, ordinary profit, and profit attributable to owners of the parent, indicating challenges in maintaining profitability. Despite these challenges, ASKA’s financial position remains stable with a slight increase in total assets. The company maintains its forecast for the full fiscal year, expecting significant growth in operating profit and ordinary profit, which suggests a positive outlook for stakeholders.
The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
ASKA Pharmaceutical Holdings Co., Ltd. reported a significant increase in sales for the first quarter of FY2025, driven by strong domestic performance and contributions from overseas operations. Despite the rise in sales, the company’s operating profit decreased due to higher costs associated with R&D and expanded business activities. The financial forecast for FY2025 remains unchanged, with expectations of continued growth in net sales and operating profit.
The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
ASKA Pharmaceutical Holdings Co., Ltd. announced the disposal of treasury stock as part of a restricted stock compensation plan aimed at incentivizing corporate officers and directors of its subsidiaries. The plan, which involves the disposal of 32,700 ordinary shares, is designed to align the interests of executives with those of shareholders over the long term, with a transfer restriction period set at 50 years. This strategic move is expected to enhance corporate value and shareholder engagement.
The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
ASKA Pharmaceutical Holdings Co., Ltd. has established an Independent Committee to enhance the fairness and objectivity of its response policies concerning large-scale purchases of company shares by entities such as Dalton Investments. The committee, composed of independent outside directors, will provide recommendations to the board of directors, ensuring transparency and protecting shareholder interests.
The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
ASKA Pharmaceutical Holdings Co., Ltd. has announced the introduction of response policies to address the large-scale purchase of its shares by Dalton Investments and associated entities. This move is aimed at safeguarding the company’s corporate value and the interests of its shareholders, as Dalton’s shareholding has increased significantly, raising concerns over potential control over the company’s financial and business policies.
The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.
ASKA Pharmaceutical Holdings Co., Ltd. has appointed Sohta Yamaguchi as the new President and Representative Director, effective June 24, 2025. This leadership change aligns with the company’s strategy to achieve its Medium-Term Management Plan goals and prepare for the next phase starting in FY2026. The transition is expected to enhance the company’s management and governance, contributing to its growth and increased corporate value.
ASKA Pharmaceutical Holdings Co., Ltd. announced its Board of Directors’ decision to oppose a shareholder proposal from NIPPON ACTIVE VALUE FUND PLC, which included agendas such as the acquisition of treasury shares and amendments to the Articles of Incorporation. The company emphasized its strategy of balancing investment in growth and shareholder returns to enhance corporate value over the medium to long term, focusing on its core pharmaceutical business and expanding into new markets and sectors.
ASKA Pharmaceutical Holdings Co., Ltd. reported its consolidated financial results for FY2024, showing a slight increase in net sales by 2.1% to 64,139 million yen. However, the company experienced a decline in operating profit and ordinary profit by 18.0% and 21.7%, respectively. The profit attributable to owners of the parent decreased significantly by 32.4%. Despite these declines, the company has increased its annual dividends per share from 40.00 yen to 55.00 yen, indicating a commitment to returning value to shareholders. Looking forward, ASKA forecasts a positive outlook for FY2025, with expected increases in net sales and profits, reflecting a strategic focus on growth and operational efficiency.
ASKA Pharmaceutical Holdings Co., Ltd.’s Board of Directors has decided to oppose a shareholder proposal from Nippon Active Value Fund PLC, which included agendas such as the acquisition of treasury shares and amendments to the articles of incorporation. The company emphasizes its commitment to enhancing corporate value through its Medium-Term Management Plan, which focuses on growth strategies in specialty areas, drug discovery, and overseas operations. The decision reflects ASKA’s strategy to balance investment in growth and shareholder returns, ensuring sustainable corporate value.
ASKA Pharmaceutical Holdings Co., Ltd. reported a 2.1% year-on-year increase in net sales to 64.1 billion yen for FY2024, driven by robust performance in its pharmaceuticals and animal health businesses. Despite rising R&D expenses impacting operating profit, the company forecasts a significant 16.9% increase in net sales and a 27.5% rise in operating profit for FY2025, indicating strong future growth prospects.
ASKA Pharmaceutical Holdings Co., Ltd. announced a decision to pay dividends of surplus with a record date of March 31, 2025, subject to approval at the upcoming Annual General Meeting. The company plans to increase its annual dividend per share to 55 yen, reflecting a 15 yen increase from the previous fiscal year, aligning with its policy of a 30% consolidated dividend payout ratio. This move underscores ASKA’s commitment to shareholder returns and stable profit distribution.
ASKA Pharmaceutical Holdings Co., Ltd. reported its consolidated financial results for FY2024, showing a slight increase in net sales by 2.1% to 64,139 million yen. However, the company experienced a decline in operating profit by 18% and ordinary profit by 21.7%, with profit attributable to owners of the parent dropping by 32.4%. Despite these declines, the company increased its annual dividends per share from 40 yen to 55 yen, indicating a commitment to returning value to shareholders. The forecast for FY2025 shows an optimistic outlook with expected growth in net sales and profits.